advertisement

Topcon

Abstract #51996 Published in IGR 14-4

Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions

Martínez-Águila A; Fonseca B; Bergua A; Pintor J
European Journal of Pharmacology 2013; 701: 213-217


In the search for new compounds to reduce intraocular pressure (IOP), with fewer side effects, we have found that agomelatine, a melatonin analogue, can reduce IOP being, therefore, interesting for the treatment of ocular hypertension and glaucoma. In normotensive conditions, agomelatine (10μl 100μM) reduced IOP by 20.8±1.4% (n=18) with a maximal effect 180min after the compound application and 68.8±5.7% (n=8) in a hypertensive condition. Concentration-response curve depicted a sigmoid behaviour presenting a pD2 value of 9.7±0.3 which was equivalent to an EC of 0.19nM. The effect of agomelatine was partially antagonized by 4PPDOT (MT antagonist receptor. 10μl 100μM) and prazosin (MT antagonist receptor. 10μl 100μM) (85.6±1.6% and 87.2±1.9%, N=18 respectively.) Agomelatine hypotensive effect in normotensive condition was comparable to latanoprost (40μl) and brimonidine (40μl) and it was no so effective as dorzolamide (40μl) or timolol (40μl). These results may suggest the use of this melatonin analogue for the treatment of those ocular conditions, which involve an abnormal raise of intraocular pressure.

Dpto de Bioquímica y Biología Molecular IV, Facultad de Óptica y Optometría, Universidad Complutense de Madrid, Madrid, Spain.

Full article

Classification:

5.3 Other (Part of: 5 Experimental glaucoma; animal models)
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)



Issue 14-4

Change Issue


advertisement

Oculus